ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Plains GP Holdings shares hit 52-week high near $28.32

Plains GP Holdings LP advanced to its highest level in a year, with Goldman Sachs upgrading the stock to Neutral and lifting its price target. The shares trade near $28.22, up 0.89% on the day.

PA
Priya Anand · Equities & Earnings Desk · 2 Sept 2026 · 04:54 · 1 min read
Share
Plains GP Holdings shares hit 52-week high near $28.32

Plains GP Holdings LP (PAGP) reached a 52-week high of $28.32 on Aug. 31, according to market data. The stock last traded at $28.22, up 0.89% on the session, after closing at $28.22 the prior day.

Goldman Sachs upgraded Plains GP Holdings from Sell to Neutral and raised its price target to $24.00 from a prior level. The bank cited a stronger crude oil macro backdrop and an improved growth outlook following the company’s sale of Canadian natural gas liquids assets.

The stock has delivered a total return of 56.2% over the past 12 months. Its dividend yield stands at 5.97%, based on current pricing. The shares have shown resilience in a volatile energy market, supported by solid free cash flow generation.

Russ Montgomery has been promoted to Vice President, Accounting and Chief Accounting Officer, effective September 2026. He joined Plains All American in 2002 and has served as Vice President, Controller since 2019. The appointment follows the retirement of Chris Herbold, the outgoing Chief Accounting Officer.

Analysts at Goldman Sachs highlighted Plains GP Holdings’ potential as a merger and acquisition candidate amid ongoing industry consolidation, reinforcing the company’s strategic positioning in the midstream energy sector.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT